SAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies USA, Inc. (“iXCells”), a cell technology company specializing in providing cell-based products and drug discovery solutions to the global academic, biotech and pharmaceutical communities, today announced completing key growth initiatives.
The company relocated to new expanded facilities in San Diego, California in July, tripling its footprint for cell product manufacturing, research, and drug discovery services, including tailored production of disease relevant cell models using CRISPR Cas9. iXCells’ chief executive, Dr. Lynn Zhang, commented, “We quickly outgrew our previous space after only a few years and this new facility offers substantially more capacity for scaling production and lab service projects integral to our customers’ preclinical development workflows.”
Dr. Nianwei Lin, the company’s President, added, “This effort is the culmination of almost twelve months of careful planning. I’m immensely proud of all our employees and their contributions in making this relocation highly successful while ensuring minimal interruption to our customer service level. To celebrate this important milestone, we’re planning to announce an exciting open-house event for our customers and suppliers later this year.”
Also in July, the company officially launched its new website, www.ixcellsbiotech.com. iXCells’ Marketing Manager, Luana Meira Williams, commented, “Our new site dramatically increases User experience from product & service browsing through to cart checkout according to UX design best practice. Some of the new features worth mentioning include a powerful global search capability, dynamic product and cell images, related product recommendations, and introduction of a customer referral and loyalty program. Moreover, we incorporated best practice content management systems integrated with our ERP system and marketing automation to deliver optimal functionality and User engagement; we believe customers, business partners, and other Users will be pleased with these new features and benefits.”
About iXCells Biotechnologies
Founded in 2014 and based in San Diego, CA, iXCells Biotechnologies is an innovative cell biology and cell technology company that provides preclinical drug discovery solutions with the focus on disease relevant cellular models enabling technologies and services to the academic, biotech and pharma communities to accelerate the pace of drug discovery. iXCells offers customers access to high quality primary and iPSC derived cells, custom iPSC services, functional bioassay development and drug screening. To learn more about this innovative leader within the preclinical iPSC sector, visit www.ixcellsbiotech.com.